insights_auto
Why is BNTX up 5.32%?
Dive Deeperchevron_right
BNTX:NASDAQ
BioNTech SE - ADR
$96.96
arrow_upward
+5.32%(+4.90) 1D
$96.96
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 9, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BNTX...
Open
$92.45
High
$97.40
Low
$92.30
Mkt. cap
24.36B
Avg. vol.
993.50K
Volume
1.32M
52-wk high
$123.98
52-wk low
$79.52
EPS
-$7.52
Beta
1.22
Shares outstanding
251.20M
No. of employees
8K
Open
$92.45
High
$97.40
Low
$92.30
Mkt. cap
24.36B
Avg. vol.
993.50K
Volume
1.32M
52-wk high
$123.98
52-wk low
$79.52
EPS
-$7.52
Beta
1.22
Shares outstanding
251.20M
No. of employees
8K
News stories
From web sources and news partners
Investing.com Nigeria
·
16 hours ago
Form 4 BioNTech SE For: 9 October By Investing.com
Stock Titan
·
20 hours ago
Under a trading plan, BioNTech (BNTX) CEO Ugur Sahin sells 36,209 and 27,000 shares.
Benzinga
·
22 hours ago
A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally
Yahoo Finance
·
1 day ago
Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR